Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPC-0501: Chemoradiotherapy Sequences and Fractionation in NPC
NCT00577057Phase 3Unknown
- Sponsor
- Hospital Authority
- Start
- Sep 2006
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Hospital Authority. Status: unknown.
02
Drugs
capecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT00577057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00577057.